Gene therapy with P53 and a fragment of thrombospondin I inhibits human breast cancer in vivo

Molecular Genetics and Metabolism

Volumn 63, Issue 2, 1998, Pages 103-109

  Xu, M ^a   Kumar, D ^a   Stass, S A ^a   Mixson, A J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Gene therapy; MDA MB 435; P53; Systemic

Indexed keywords

LIPOSOME; PROTEIN P53; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE THERAPY; METASTASIS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALIA; MUS MUSCULUS;

EID: 0031685633     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1997.2654     Document Type: Article

References (24)

1. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-nega-tive Flk-1 mutant. Nature 367:576-579, 1994.
2. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401, 1996.
3. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J NCI 87:581-586, 1995.
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosalind RA, Moses M, Snae WS, Cao Y, Sage EH, Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994.
5. Maione TE, Gray GS, Petro J, Donner AJ, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet 4 and related peptides. Science 247:77-79, 1990.
6. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 2:689-692, 1996.
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997.
8. Tilkins ML, Hawley-Nelson P, Batiste PJ. Transient transfection of endothelial Cells. Focus 16:117-119, 1994.
9. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249:1285-1287, 1990.
10. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715, 1990.
11. Cheng J, Yee J-K, Yeargin J, Friedman T, Haas M. Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res 52:222-226, 1992.
12. Fujiwara T, Cai DW, Georges R, Mukhopakhyay T, Grimm EA, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994.
13. Roth JA, Nguyen D, Lawrence DD, Kemp BI, Carrasco CH, Person DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han C-I, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2:985-991, 1996.
14. Lesoon-Wood L, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth of a malignant human breast cancer in nude mice. Human Gene Ther 6:395-405, 1995.
15. Xu M, Kumar D, Srinivas S, DeTolla LJ, Yu SF, Stass SA, Mixson AJ. Parenteral Gene Therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Human Gene Ther. 8:177-185, 1996.
16. Roth JA. Restoration of p53 function using Gene Therapy. Presented at the Second Annual New Cancer Strategies, April 1997, p. 53.
17. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I. Science 265:1582-1584, 1995.
18. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54:6504-6511, 1994.
19. Roemer K, Friedmann T. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann NY Acad Sci 716:265-280, 1994.
20. Stomblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 6:462-467, 1996.
21. Tolsma VS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin 1 have anti-angiogenic activity. J. Cell Biol 122:497-511, 1993.
22. Butke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 157:233-240, 1993.
23. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct integrins. Science 270:1500-1502, 1995.
24. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211, 1993.